Generic Name and Formulations:
Ambrisentan 5mg, 10mg; tabs.
Gilead Sciences, Inc.
Indications for LETAIRIS:
Pulmonary arterial hypertension (PAH) (WHO Group I) in patients with WHO Class II or III symptoms to improve exercise ability and delay clinical worsening, or in combination with tadalafil to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability.
In females: initiate only after (–) pregnancy test. Swallow whole. Initially 5mg once daily, with or without tadalafil 20mg once daily. At 4-week intervals, either Letairis or tadalafil dose may be increased, as needed and tolerated, to Letairis 10mg or tadalafil 40mg. Concomitant cyclosporine: max 5mg once daily.
Pregnancy (Cat.X). Idiopathic pulmonary fibrosis including those patients with pulmonary hypertension (WHO Group 3).
Embryo-fetal toxicity: in females of reproductive potential, exclude pregnancy prior to starting, monthly during, and for 1 month after treatment; must use acceptable methods of contraception. Monitor for significant fluid retention and pulmonary edema; discontinue if pulmonary veno-occlusive disease develops. Monitor hemoglobin prior to initiation, at one month, and periodically thereafter; consider discontinuing if significant decrease in hemoglobin develops. Clinically significant anemia: not recommended. Moderate to severe hepatic impairment: not recommended. Discontinue if ALT, AST elevations >5xULN or if elevations accompanied by bilirubin >2xULN, or by signs/symptoms of liver dysfunction and other causes excluded. Nursing mothers: not recommended.
Potentiated by cyclosporine. Increased peripheral edema with concomitant tadalafil.
Endothelin receptor antagonist.
Peripheral edema, nasal congestion, sinusitis, flushing, elevated liver enzymes; decreased sperm counts, hematologic changes; in combination with tadalafil: also headache, cough, anemia, dyspepsia, bronchitis.
For all female patients: available only through the Letairis REMS program. To enroll call (866) 664-5327 or www.letairisrems.com.
Rheumatology Advisor Articles
- Topical vs Oral NSAIDs for Rheumatoid Arthritis: Examining Cardiovascular Risks
- Update: 2017 Treat-to-Target Recommendations for Spondyloarthritis
- Risk for COPD, Asthma Examined in Women With Rheumatoid Arthritis
- Host Genetics May Affect Intestinal Microbiota Composition in Reactive Arthritis
- Introduction of bDMARDs Linked to Reduced Incidence of Total Knee Replacement
- Alogliptin May Be Associated With Lower Fracture Risk Compared With Linagliptin, Saxagliptin
- Managing Treatment Nonadherence in Rheumatic Diseases
- Hyperuricemia in Psoriatic Arthritis: Identifying Features to Improve Outcomes
- Routine Vitamin D, Calcium Supplementation Not Associated With Fracture Reduction in Older Adults
- Examining the Implications of Accelerated Coronary Plaque Formation in Psoriatic Arthritis
- Assessment of Nitrated Nucleosome Levels and Neuropsychiatric Events in Systemic Lupus Erythematosus
- Clinicians Who Share Email Addresses With Patients Have Higher Satisfaction Scores
- Biosimilar LBEC0101 Equivalent to ETN-RP for RA Unresponsive to Methotrexate
- Adalimumab Demonstrated Superior Efficacy Over Standard of Care in Refractory Uveitis
- Clinician Counseling for Exercise Increased Among Adults With Arthritis Between 2002 and 2014